Part No: P184 rev 2Issued year: 2018File size: 0.93mbFile type: pdf
Traditionally the analysis of aldosterone and angiotensin (for plasma renin activity measurement) are performed separately. However, the relationship of the aldosterone-to-renin-ratio is a very useful tool to help define the cause of secondary hypertension. This poster compares sample preparation options for the simultaneous extraction of Angiotensin I, II and Aldosterone from plasma.
MSACL EU 2018
MSACL NA 2019
Part No: AN750Issued year: 2012File size: 1.14mbFile type: pdf
This application note describes the extraction of several peptides, ranging in size from a 7mer to a 54mer, from plasma and serum using EVOLUTE® ABN in a 96-well plate format. The presence of certain proteins and peptides in human biological matrices can be used as diagnostic markers for the onset of disease and other health problems in humans. The ability to detect and monitor lower levels of peptides can aid in clinical patient health assessments and therapeutic drug level determinations. The sample preparation methodology detailed in this application note can significantly increase sensitivity and detection of peptides from biological matrices on LC/MS/MS. This application note offers the user two different elution strategies due to the extensive combination of peptides that may need to be extracted either strategy may be suitable dependent upon which peptides are relevant.
Peptides, EVOLUTE, SPE, Solid Phase Extraction, Proteins,
Part No: P049Issued year: 2012File size: 0.27mbFile type: pdf
This poster outlines a new method for the extraction of a mixture of peptides from plasma using resin based SPE. Initial method optimization was performed using EVOLUTE ABN before comparison to the streamlined approach without plate conditioning and equilibration using EVOLUTE EXPRESS ABN. Presented at EBF 2012.
EBF, EBF 2012, Peptide, ABN, SPE, Polymer, Polymeric,
Part No: AN894Issued year: 2018File size: 1.17mbFile type: pdf
This application note describes the simultaneous extraction of aldosterone at low (< 25pg/mL) concentration and angiotensin I and II from plasma, with the potential to improve throughput and reduce time and costs in PRA determination.